| Full Name | Ruth Maguta |
|---|---|
| Gender | Female |
| Speciality | Psychologist - Intellectual & Developmental Disabilities |
| Location | 107 Dasher Ave, Bear, Delaware |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003415985 | NPI | - | NPPES |
| 250083818 | Medicaid | DE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103TM1800X | Psychologist - Intellectual & Developmental Disabilities | (Delaware) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ruth Maguta, 107 Dasher Ave, Bear, DE 19701-1193 Ph: (302) 345-8630 | Ruth Maguta, 107 Dasher Ave, Bear, DE 19701-1193 Ph: (302) 345-8630 |
News Archive
ulrich medical USA, Inc., today announced the U.S. market release of the tezo spine implants for multiple surgical approaches to lumbosacral interbody fusion.
Popular fiction that normalizes and glamorizes violence against women, such as the blockbuster Fifty Shades series, may be associated with a greater risk of potentially harmful health behaviors and risks.
NewYork-Presbyterian Morgan Stanley Children's Hospital is the only medical center in the United States to offer minimally invasive liver donation for pediatric transplantation. Surgeons use a laparoscopic technique to remove a section of liver from a living donor for implantation in a pediatric patient - typically a parent donating to their child. The innovative approach promises dramatically improved recovery for the donor.
Cases of endocarditis - infection of the heart valves - have risen dramatically in recent years as a result of the opioid crisis. In London, Ontario 55 per cent of people who experience heart valve infections are injection drug users. They are particularly vulnerable to the disease and a third die as a result.
Semafore Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's SF1126 product candidate for the treatment of B-cell chronic lymphocytic leukemia (CLL). In April 2010, the Company initiated an expansion of its ongoing Phase I clinical study into this disease setting. SF1126 is a novel peptidic prodrug that converts to LY294002, one of the most widely studied small molecule inhibitors of both phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR).
› Verified 6 days ago
Kathleen Owens, Psychologist Medicare: Not Enrolled in Medicare Practice Location: 925 Bear Corbitt Rd, Bear, DE 19701 Phone: 302-454-2400 Fax: 302-454-5442 | |
Fatimah Rasul-pettigrew, Psychologist Medicare: Not Enrolled in Medicare Practice Location: 925 Bear Corbitt Rd, Bear, DE 19701 Phone: 267-258-7419 | |
Mary Eleanor Esposito, Psychologist Medicare: Not Enrolled in Medicare Practice Location: 925 Bear Corbitt Rd, Bear, DE 19701 Phone: 302-454-2400 | |
Stacey Scot-mason, Psychologist Medicare: Not Enrolled in Medicare Practice Location: 3 Gullane Ln, Bear, DE 19701 Phone: 301-648-3213 | |
Maureen Dugan, Psychologist Medicare: Not Enrolled in Medicare Practice Location: 925 Bear Corbitt Rd, Bear, DE 19701 Phone: 302-454-2400 Fax: 302-454-5442 | |
Kathleen Eaken, Psychologist Medicare: Not Enrolled in Medicare Practice Location: 925 Bear Corbitt Rd, Bear, DE 19701 Phone: 302-454-2400 Fax: 302-454-5442 |